By establishing a mechanistic link between tau burden, EC neural dynamics, and learning behavior, our study positions EC activity as both a clinically relevant biomarker and a potential therapeutic target for preserving cognitive function in AD. This evidence concerns the gene MAPT and Alzheimer disease.